Orca Bio to Build Facility to Manufacture 3,000 Cell Therapy Products Annually

Orca Bio will be expanding its current manufacturing capabilities through the construction of a 100,000 square foot commercial facility in Sacramento, Calif.

The new facility is intended to support the late-stage clinical development and commercialization of Orca Bio’s precision cell therapies, including Orca-T, which is currently being evaluated in a phase 3 trial.

One of the new facility highlights is the capacity to manufacture approximately 3,000 cell therapy products per year, said the company.

The construction is scheduled to be completed later this year. The facility is expected to be fully validated and operational in the first half of 2023.